Dynavax completes enrollment in allergy Phase II/III

DVAX completed enrollment of 462 ragwood allergy patients in a double-blind, placebo-controlled U.S. Phase II/III trial of its AIC. The primary endpoint is change in nasal symptom scores compared with placebo following the 2005 ragweed season. An interim analysis is scheduled for after the 2004 ragweed season. ...